AC
APLS

Athanor Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Athanor Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,565
Closed -$261K – 808
2020
Q4 		$261K Sell
4,565
-2,152
-32% -$91K 0.01% 598
2020
Q3 		$203K Sell
6,717
-3,187
-32% -$95.2K 0.01% 490
2020
Q2 		$323K Buy
+9,904
New +$318K 0.02% 395
2020
Q1 		– Sell
-16,300
Closed -$499K – 173
2019
Q4 		$499K Sell
16,300
-8,200
-33% -$227K 0.02% 244
2019
Q3 		$590K Buy
24,500
+9,300
+61% +$256K 0.04% 142
2019
Q2 		$385K Buy
+15,200
New +$309K 0.05% 104

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Athanor Capital's APLS Position: Q1 2021 in Review

Athanor Capital sold out of Apellis Pharmaceuticals (APLS) in Q1 2021, closing a stake of 4,565 shares — an estimated $261K sold.

Athanor Capital first reported a position in APLS in Q2 2019 and held it in 6 quarters. The position peaked at $590K in Q3 2019. 175 funds tracked by Wall St. Rank hold APLS as of Q1 2021.

  • Athanor Capital reported no remaining Apellis Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Athanor Capital sold 4,565 Apellis Pharmaceuticals shares in Q1 2021, an estimated $261K.
  • Athanor Capital first reported a position in Apellis Pharmaceuticals in Q2 2019 and held it in 6 quarters.
  • Athanor Capital's Apellis Pharmaceuticals position peaked at $590K in Q3 2019.
  • 175 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.